Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
1.080
+0.010 (0.93%)
May 2, 2025, 4:00 PM EDT - Market closed
Company Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.
The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers.
It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug.
Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Acumen Pharmaceuticals, Inc.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jul 1, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 61 |
| CEO | Daniel O'Connell |
Contact Details
Address: 1210-1220 Washington St., Suite 210 Newton, Massachusetts 02465 United States | |
| Phone | 617 344 4190 |
| Website | acumenpharm.com |
Stock Details
| Ticker Symbol | ABOS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001576885 |
| CUSIP Number | 00509G209 |
| ISIN Number | US00509G2093 |
| Employer ID | 36-4108129 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Daniel J. O'Connell M.B.A. | Chief Executive Officer and Director |
| Matt Zuga | Chief Financial Officer and Chief Business Officer |
| Derek M. Meisner Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. James Doherty Ph.D. | President and Chief Development Officer |
| Dr. Grant A. Krafft Ph.D. | Co-Founder |
| Dr. Caleb E. Finch Ph.D. | Co-Founder |
| Dr. William L. Klein Ph.D. | Co-Founder |
| Russell Barton M.S. | Chief Operating Officer |
| Kelly Carranza | Vice President, Finance and Accounting and Corporate Controller |
| Alex Braun M.B.A. | Vice President and Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 31, 2025 | SCHEDULE 13D/A | Filing |
| Mar 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Jan 23, 2025 | 144 | Filing |
| Jan 21, 2025 | 144 | Filing |
| Jan 21, 2025 | 144 | Filing |